The present invention relates to a computer system (1) for setting adjustment values of a blood treatment apparatus (100), comprising a first input interface (I1), a second input interface (I2), as well as an output interface. Furthermore, having a calculation device (5) and a display device (I3), whereby the calculation device (5) is programmed, after reading a target value for the renal dose via a blood treatment apparatus (100), to display to the user in a graphic via the display device (I3), a selection range (A) from a number of combinations (K1, K2, K3), each of exactly one adjustable value, (Q;.sup.⋅.sub.1, Q;⋅.sub.2, Q;⋅.sub.3) for the flow of the blood pump (101), on the one hand, and precisely one adjustable value ({dot over (D)}1, {dot over (D)}2, {dot over (D)}3) for the flow of the dialysis liquid pump (121), on the other. Based on the displayed selection range A, the user can select one of the displayed combinations via a second input interface (I2). The calculation device (5) is further programmed so that the adjustable value (Q;.sup.⋅.sub.B) for the blood pump (101) and the adjustable value ({dot over (D)}.sub.B) for the dialysis liquid pump (121) of the selected combination (K.sub.B) can be given via the output interface.

A CRRT apparatus comprising a filtration unit (2), a blood circuit (17), a blood pump (21), a dialysate line (13) and one or more lines (8; 51; 57; 58; 63; 69; 67; 74) to transfer a respective solution into blood; a fluid source for each of said one or more lines, wherein said solution comprises at least one buffer agent in the form of bicarbonate or bicarbonate precursor. A control unit (12) is configured to receive a patient prescription and to determine a parameter (J.sub.buffer_load/BW) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment, wherein said parameter is determined as a function of the concentration of said buffer agent in said fluid source and as a function of the estimated or calculated patient systemic steady state concentration of bicarbonate and/or bicarbonate precursors.

A blood filtration system may include blood circuit configured to transmit a fluid within one or more lumens. The system may include an optical sensor configured to couple with the blood circuit. The optical sensor may measure one or more optical characteristics of the fluid in the blood circuit. The one or more optical characteristics may include a first optical characteristic corresponding to a concentration of an imaging substance in the fluid within the blood circuit. The system may include a controller in communication with the optical sensor. The controller may include a sampling module configured to record the one or more optical characteristics. The controller may include a physiological characteristic identification module configured to determine a plasma volume of the patient with the recorded optical characteristics of the imaging substance.

The disclosed subject matter relates to extracorporeal blood processing or other processing of fluids. Volumetric fluid balance, a required element of many such processes, may be achieved with multiple pumps or other proportioning or balancing devices which are to some extent independent of each other. This need may arise in treatments that involve multiple fluids. Safe and secure mechanisms to ensure fluid balance in such systems are described.

There is provided a technique for detecting leakage in extracorporeal blood circulation while suppressing increased cost in a dialysis device. A dialysis device includes an artery-side blood circuit, a dialyzer, and a vein-side blood circuit. The dialysis device detects an abnormality based on a difference between theoretical value and measured value of a blood concentration in the vein-side blood circuit. The theoretical value of the blood concentration in the vein-side blood circuit is specified based on blood concentration and blood flow rate in the artery-side blood circuit and a water removal rate in the dialyzer.

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.

Dialysis systems comprising actuators that cooperate to perform dialysis functions and sensors that cooperate to monitor dialysis functions are disclosed. According to one aspect, such a hemodialysis system comprises a user interface model layer, a therapy layer, below the user interface model layer, and a machine layer below the therapy layer. The user interface model layer is configured to manage the state of a graphical user interface and receive inputs from a graphical user interface. The therapy layer is configured to run state machines that generate therapy commands based at least in part on the inputs from the graphical user interface. The machine layer is configured to provide commands for the actuators based on the therapy commands.

The present disclosure relates to a control device or closed-loop control device, programmed to control or regulate a blood treatment apparatus during a treatment of a patient's blood carried out in a treatment session using an extracorporeal blood tubing set and the blood treatment apparatus while balancing liquid flows and conveying via different liquid pumps. The control device or closed-loop control device is further programmed to interrupt the balancing and/or the liquid flows at one or more predetermined interruption time points which lie within the duration of the treatment session.

The present disclosure relates to a method for determining or recommending a time point for measuring a patient's pressure readings during a blood treatment session. The method encompasses monitoring the ultrafiltration rate with which the patient's blood is treated, a relative blood volume, and/or a sodium concentration or a change in any of these, for the existence of, or meeting any pre-determined criterion for the ultrafiltration, the relative blood volume, and/or the sodium concentration, or the change thereto. Furthermore, the method encompasses transmitting a signal to a blood pressure measuring device when the pre-determined criterion for the ultrafiltration rate, the relative blood volume, and/or the sodium concentration or the change thereto is met.

A parameter for controlling an inlet pump speed in a hemofiltration system is derived from fitting a line to multiple data points of pressure versus pump speed. The pressure is measured in a channel connecting an inlet pump to an outlet pump. First, the inlet pump operates and the pressure is sampled until it is stabilized, then the inlet pump speed is increased and pressure is measured to obtain a data point. Subsequently the inlet pump speed is decreased and pressure is measured to obtain another data point. A line is fit through the data points to obtain the parameter.